Treace Medical Q3 revenue $21.6M (+52% YoY); net loss ($6.4M); FY21 guidance reaffirmed $90-95M

TREACE MEDICAL CONCEPTS, INC.

2022-Q3 EPS reported -$0.30 revenue$60,980,000

Revenue $21.6M, up 52% YoY from $14.3M; gross margin 80.4% (+80 bps).
Net loss ($6.4M) or ($0.12) per share vs ($2.8M) or ($0.08) in Q3 2020.
Full-year 2021 revenue guidance reaffirmed at $90M-$95M (57-65% growth).
Cash $109.5M; launched Adductoplasty System; appointed two new board members.
ALIGN3D study showed 0.9% recurrence at 12 months; first Mini3D patient treated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.